07.04.2017
Fresenius SE & Co. KGaA DE0005785604
DGAP-Adhoc: Fresenius SE & Co. KGaA: Fresenius SE & Co. KGaA confirms discussions with Akorn, Inc.
DGAP-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Mergers & Acquisitions
Fresenius SE & Co. KGaA: Fresenius SE & Co. KGaA confirms discussions with
Akorn, Inc.
07-Apr-2017 / 22:54 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by
DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Fresenius SE & Co. KGaA confirms that Fresenius Kabi is currently in
discussions with Akorn, Inc., a US specialty generic pharmaceutical company,
concerning a potential acquisition of Akorn, Inc. Akorn, Inc. shares are
listed on the NASDAQ Global Select Market.
Entry into a formal agreement of a transaction remains subject to, among
other things, approval by the Executive Board and Supervisory Board of
Fresenius Management SE and the board of directors of Akorn, Inc. There can
be no assurance any transaction will result from these discussions, or as to
the terms of any such transaction. Neither Fresenius SE & Co. KGaA nor
Akorn, Inc. intend to make any additional comments regarding these
negotiations unless and until it is appropriate to do so, or a formal
agreement has been reached.
Fresenius SE & Co. KGaA,
represented by Fresenius Management SE
The Executive Board
Bad Homburg v.d.H., 7 April 2017
Contact:
Markus Georgi
Senior Vice President Investor Relations
T: +49 (0) 6172 608-2485
[email protected]
End of note
---------------------------------------------------------------------------
07-Apr-2017 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Germany
Phone: +49 (0)6172 608-2485
Fax: +49 (0)6172 608-2488
E-mail: [email protected]
Internet: www.fresenius.com
ISIN: DE0005785604
WKN: 578560
Indices: DAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime
Standard), Munich; Regulated Unofficial Market in Berlin,
Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxemburg
End of Announcement DGAP News Service
---------------------------------------------------------------------------
563471 07-Apr-2017 CET/CEST
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Fresenius SE & Co. KGaA ISIN: DE0005785604 können Sie bei EQS abrufen
Medtech , 578560 , FRE , XETR:FRE